Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.
Longfield
Viki
V
Gebhart
Brenda
B
Hayward
Lynn
L
D000740:Anemia / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D003362:Cost-Benefit Analysis; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000032:analysis; D018718:Home Infusion Therapy; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D011994:Recombinant Proteins; D012189:Retrospective Studies; D013810:Therapeutic Equivalency
D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa